STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 164

TO: Dwayne C Jones **Location: rem/3B87/3C70** **Art Unit: 1614** **Thursday, April 27, 2006** **Case Serial Number: 10/750118**	**From: Mary Jane Ruhl** **Location: Biotech-Chem Library** **Remsen 1-A-62** **Phone: 571-272-2524** **maryjane.ruhl@uspto.gov**

Search Notes

Examiner Jones,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl
Technical Information Specialist
STIC
Remsen 1-A-62
Ext. 22524

```
=> d que stat l19
L9            4 SEA FILE=REGISTRY ABB=ON  (SIBUTRAMINE/CN OR "SIBUTRAMINE
                HYDROCHLORIDE"/CN OR "SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE"/CN
                 OR "SIBUTRAMINE METHANESULFONATE"/CN)
L10         532 SEA FILE=HCAPLUS ABB=ON  L9
L11         190 SEA FILE=HCAPLUS ABB=ON  L10 AND (?EPILEPTIC? OR ?DEPRESS?)
L17          97 SEA FILE=HCAPLUS ABB=ON  L11 AND (?ANTIEPILEPTIC? OR ?ANTIDEPRE
                SSANT? OR ?ANTI(W)(?EPILEPTIC OR DEPRESSANT?))
L18           3 SEA FILE=HCAPLUS ABB=ON  L17 AND (?CONTROL? OR ?TIME?)(W)?RELEA
                S?
L19           3 SEA FILE=HCAPLUS ABB=ON  L18 AND (PRD<20031231 OR PD<20031231)

=> d ibib abs l19 1-3

L19  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:493467  HCAPLUS
DOCUMENT NUMBER:          143:38409
TITLE:                    Combination drug therapy to treat obesity
INVENTOR(S):              Seed, John C.
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 47 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005051297         A2    20050609    WO 2004-US38981         20041119 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2005143350         A1    20050630    US 2004-993496          20041118 <--
PRIORITY APPLN. INFO.:                       US 2003-523610P      P  20031119 <--
                                             US 2004-993496       A  20041118

AB   Provided are methods of achieving desirable weight loss in an overweight or
     obese individual by administering at least one anticholinesterase agent
     and at least one antidepressant. The invention also provides
     for pharmaceutical compns. and kits for simultaneous delivery of at least
     one anticholinesterase agent and at least one antidepressant.

L19  ANSWER 2 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:241329  HCAPLUS
DOCUMENT NUMBER:          136:284433
TITLE:                    Administration of phosphodiesterase inhibitors for the
                          treatment of premature ejaculation
INVENTOR(S):              Wilson, Leland F.; Doherty, Paul C.; Place, Virgil A.;
                          Smith, William L.; Abdel-Hamid, Abdou Ali Ibrahim
                          Aboubakr
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S.
```

Ser. No. 467,094.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002037828	A1	20020328	US 2001-888250	20010621 <--
US 6403597	B2	20020611		
US 6037346	A	20000314	US 1998-181070	19981027 <--
US 6548490	B1	20030415	US 1999-467094	19991210 <--
CA 2451152	AA	20030103	CA 2002-2451152	20020325 <--
WO 2003000343	A2	20030103	WO 2002-US9415	20020325 <--
WO 2003000343	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1418896	A2	20040519	EP 2002-717729	20020325 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005519851	T2	20050707	JP 2003-506984	20020325 <--

PRIORITY APPLN. INFO.:

US 1997-958816	B2	19971028 <--
US 1998-181070	A2	19981027 <--
US 1999-467094	A2	19991210 <--
US 2001-888250	A	20010621 <--
WO 2002-US9415	W	20020325 <--

AB A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided. Zaprinast 1.0, mannitol 1.0, microcryst. cellulose 2.0, and magnesium stearate 10 mg are blended in a suitable mixer and then compressed into sublingual tablets. Each sublingual tablet contains 10 mg zaprinast.

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:396644 HCAPLUS
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001037808	A1	20010531	WO 2000-US32255	20001122 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123 <--
CA 2391923	AA	20010531	CA 2000-2391923	20001122 <--
EP 1233756	A1	20020828	EP 2000-980761	20001122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517470	T2	20030527	JP 2001-539423	20001122 <--
PRIORITY APPLN. INFO.:			US 1999-447690 A	19991123 <--
			WO 2000-US32255 W	20001122 <--

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d que stat l20
L9            4 SEA FILE=REGISTRY ABB=ON  (SIBUTRAMINE/CN OR "SIBUTRAMINE
                HYDROCHLORIDE"/CN OR "SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE"/CN
                 OR "SIBUTRAMINE METHANESULFONATE"/CN)
L10         532 SEA FILE=HCAPLUS ABB=ON  L9
L11         190 SEA FILE=HCAPLUS ABB=ON  L10 AND (?EPILEPTIC? OR ?DEPRESS?)
L17          97 SEA FILE=HCAPLUS ABB=ON  L11 AND (?ANTIEPILEPTIC? OR ?ANTIDEPRE
                SSANT? OR ?ANTI(W)(?EPILEPTIC OR DEPRESSANT?))
L18           3 SEA FILE=HCAPLUS ABB=ON  L17 AND (?CONTROL? OR ?TIME?)(W)?RELEA
                S?
L20           1 SEA L18

=> d ibib abs l20 1-1

L20  ANSWER 1 OF 1  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:   2003039160  EMBASE
TITLE:              Academic detailing of meperidine at a teaching hospital.
AUTHOR:             Boothby L.A.; Wang L.-J.; Mayhew S.; Chestnutt L.
CORPORATE SOURCE:   Dr. L.A. Boothby, 710 Center Street, Columbus, GA 31902,
                    United States. lisa.boothby@crhs.net
SOURCE:             Hospital Pharmacy, (1 Jan 2003) Vol. 38, No. 1, pp. 30-35.
                    .
                    Refs: 36
                    ISSN: 0018-5787  CODEN: HOPHAZ
COUNTRY:            United States
DOCUMENT TYPE:      Journal; Article
FILE SEGMENT:       037     Drug Literature Index
                    038     Adverse Reactions Titles
LANGUAGE:           English
SUMMARY LANGUAGE:   English
ENTRY DATE:         Entered STN: 20 Feb 2004
                    Last Updated on STN: 20 Feb 2004
```

AB Meperidine (Demerol) is an opiate analgesic that is not considered first-line therapy for most pain management indications because of concerns about its safety and efficacy. Inpatient data from a 417-bed community teaching hospital revealed high use of meperidine in oral, IM, and IV forms. A multifaceted academic detailing approach was employed to change prescribing behavior and decrease meperidine use. This approach included conducting two concurrent Medication Use Evaluations; Grand Rounds presentations for pharmacy staff, nurses, and medical residents; solicitation of opinion leaders; pocket and table-top cards; newsletter articles; and provision of pharmaceutical care. Comparing the number of meperidine doses dispensed per adjusted patient day before and after the intervention, use was reduced by 0.0966 doses per patient ($P < 0.05$: 95% CI, 0.0955 to 0.0977). The number of patients receiving meperidine was reduced by 2.43% ($P < 0.05$: 95% CI, 1.97 to 2.88). This translates into a relative reduction of 29.5% in patients receiving meperidine and a relative reduction of 31% in meperidine doses dispensed per patient after academic detailing initiatives vs before. Eighty-five percent of standard orders were changed to improve therapy; these changes included converting meperidine to morphine or hydromorphone, decreasing cumulative acetaminophen daily dosages, using controlled-release and immediate-release opioids for pain management when oral therapy was tolerated, and combining modalities with different mechanisms of action for synergy and to decrease potential adverse effects from larger dosages of single entities. Academic detailing of meperidine resulted in short-term changes in prescribing patterns and decreased meperidine use at this institution. Long-term implications for pain management have not yet been assessed.

```
=> => d que stat l22
L9             4 SEA FILE=REGISTRY ABB=ON  (SIBUTRAMINE/CN OR "SIBUTRAMINE
                  HYDROCHLORIDE"/CN OR "SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE"/CN
                   OR "SIBUTRAMINE METHANESULFONATE"/CN)
L10          532 SEA FILE=HCAPLUS ABB=ON  L9
L11          190 SEA FILE=HCAPLUS ABB=ON  L10 AND (?EPILEPTIC? OR ?DEPRESS?)
L17           97 SEA FILE=HCAPLUS ABB=ON  L11 AND (?ANTIEPILEPTIC? OR ?ANTIDEPRE
                  SSANT? OR ?ANTI(W)(?EPILEPTIC OR DEPRESSANT?))
L18            3 SEA FILE=HCAPLUS ABB=ON  L17 AND (?CONTROL? OR ?TIME?)(W)?RELEA
                  S?
L21           51 SEA FILE=USPATFULL ABB=ON  L18 AND (PRD<20031231 OR PD<20031231
                  )
L22            5 SEA FILE=USPATFULL ABB=ON  L21 AND ?DYSKINESIA?

=> d ibib abs l22 1-5

L22  ANSWER 1 OF 5  USPATFULL on STN
ACCESSION NUMBER:         2005:209618  USPATFULL
TITLE:                    Substituted 2,3-diphenyl pyridines
INVENTOR(S):              Finke, Paul E, Milltown, NJ, UNITED STATES
                          Meurer, Laura C., Scotch Plains, NJ, UNITED STATES
                          Debenham, John S., Scotch Plains, NJ, UNITED STATES
                          Toupence, Richard B., South Plainfield, NJ, UNITED
                          STATES
                          Walsh, Thomas F., Watchung, NJ, UNITED STATES

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2005182103      A1   20050818
APPLICATION INFO.:        US 2003-508043     A1   20030324  (10)
                          WO 2003-US9005           20030324

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2002-60368334   20020328                <--
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ,
                          07065-0907, US
NUMBER OF CLAIMS:         21
EXEMPLARY CLAIM:          1
LINE COUNT:               5290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Novel compounds of the structural formula (I) are antagonists and/or
       inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in
       the treatment, prevention and suppression of diseases mediated by the
       CB1 receptor. The compounds of the present invention are useful as
       centrally acting drugs in the treatment of psychosis, memory deficits,
       cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders
       including multiple sclerosis and Guillain-Barre syndrome and the
       inflammatory sequelae of viral encephalitis, cerebral vascular
       accidents, and head trauma, anxiety disorders, stress, epilepsy,
       Parkinson s disease, movement disorders, and schizophrenia. The
       compounds are also useful for the treatment of substance abuse
       disorders, the treatment of obesity or eating disorders, as well as the
       treatment of asthma, constipation, chronic intestinal
       pseudo-obstruction, and cirrhosis of the liver.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L22 ANSWER 2 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2005:31478 USPATFULL
TITLE: 2-Aminoquinoline compounds
INVENTOR(S): DeVita, Robert J., Westfield, NJ, UNITED STATES
Chang, Lehua, Ramsey, NJ, UNITED STATES
Chaung, Danny, Clark, NJ, UNITED STATES
Hoang, MyLe, Colonia, NJ, UNITED STATES
Jiang, JinLong, Scotch Plains, NJ, UNITED STATES
Lin, Peter, Edison, NJ, UNITED STATES
Sailer, Andreas W., Edison, NJ, UNITED STATES
Young, Jonathan R., Kendall Park, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005026915	A1	20050203	
APPLICATION INFO.:	US 2004-496615	A1	20040525	(10)
	WO 2002-US37556		20021122	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-333581P	20011127 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 4617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with compounds of the general Formula I: ##STR1##

and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2005:11680 USPATFULL
TITLE: 4-Aminoquinoline compounds
INVENTOR(S): DeVita, Robert J., Westfield, NJ, UNITED STATES
Chang, Lehua, Ramsey, NJ, UNITED STATES
Hoang, MyLe Thi, Colonia, NJ, UNITED STATES
Jiang, JinLong, Scotch Plains, NJ, UNITED STATES
Lin, Peter, Edison, NJ, UNITED STATES
Sailer, Andreas W., Edison, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009815	A1	20050113
APPLICATION INFO.:	US 2004-496614	A1	20040525 (10)
	WO 2002-US37510		20021122

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333464P	20011127 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 4150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with compounds of the general Formula I: ##STR1##

and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2004:315279 USPATFULL
TITLE: Substituted imidazoles as cannabinoid receptor modulators
INVENTOR(S): Hagmann, William K, Westfield, NJ, UNITED STATES
Qi, Hongbo, Edison, NJ, UNITED STATES
Shah, Shrenik K., Metuchen, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248956	A1	20041209
APPLICATION INFO.:	US 2004-501060	A1	20040709 (10)
	WO 2003-US2851		20030124

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-352743P	20020129 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1

LINE COUNT: 2706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the present invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammnatory disorders including multiple sclerosis and Guillain-Barr syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. Particular novel compounds of structural formula (I) are also claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2003:166637 USPATFULL
TITLE: Substituted imidazoles as cannabinoid receptor modulators
INVENTOR(S): Finke, Paul E., Milltown, NJ, UNITED STATES
Mills, Sander G., Scotch Plains, NJ, UNITED STATES
Plummer, Christopher W., Keasbey, NJ, UNITED STATES
Shah, Shrenik K., Metuchen, NJ, UNITED STATES
Truong, Quang T., Edison, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003114495	A1	20030619	<--
APPLICATION INFO.:	US 2002-198442	A1	20020717 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-307224P	20010720 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 3593
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and

complications associated therewith. Novel compounds of structural formula (I) are also claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his ful

     (FILE 'HOME' ENTERED AT 12:45:20 ON 27 APR 2006)

     FILE 'REGISTRY' ENTERED AT 13:15:26 ON 27 APR 2006
                E SIBUTRAMINE/CN
L9             4 SEA ABB=ON  (SIBUTRAMINE/CN OR "SIBUTRAMINE HYDROCHLORIDE"/CN
                  OR "SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE"/CN OR "SIBUTRAMINE
                  METHANESULFONATE"/CN)

     FILE 'HCAPLUS' ENTERED AT 13:15:49 ON 27 APR 2006
L10          532 SEA ABB=ON  L9
L11          190 SEA ABB=ON  L10 AND (?EPILEPTIC? OR ?DEPRESS?)
L12            2 SEA ABB=ON  L11 AND ?DYSKINESIA?
L13            2 SEA ABB=ON  L9 AND ?DYSKINESIA?
L14            5 SEA ABB=ON  (L11 OR L13) AND (?CONTROL? OR ?TIME?)(W)?RELEAS?
                  E MUELLER PETER/AU
                  E MUELLER PETER STERLING/AU
L15           19 SEA ABB=ON  ("MUELLER PETER S"/AU OR "MUELLER PETER STERLING"/A
                  U)
L16            3 SEA ABB=ON  L15 AND ?SIBUTRAMINE?
L17           97 SEA ABB=ON  L11 AND (?ANTIEPILEPTIC? OR ?ANTIDEPRESSANT? OR
                  ?ANTI(W)(?EPILEPTIC OR DEPRESSANT?))
L18            3 SEA ABB=ON  L17 AND (?CONTROL? OR ?TIME?)(W)?RELEAS?
L19            3 SEA ABB=ON  L18 AND (PRD<20031231 OR PD<20031231)  3 cits from CA File

     FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 13:25:43 ON
     27 APR 2006
L20            1 SEA ABB=ON  L18  1 cit from 5 databases

     FILE 'USPATFULL' ENTERED AT 13:26:19 ON 27 APR 2006
L21           51 SEA ABB=ON  L18 AND (PRD<20031231 OR PD<20031231)
L22            5 SEA ABB=ON  L21 AND ?DYSKINESIA?  5 cits from USPatFull

     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   26 APR 2006  HIGHEST RN 882003-29-4
     DICTIONARY FILE UPDATES:  26 APR 2006  HIGHEST RN 882003-29-4

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
```

for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CASREACT

FILE CONTENT:1840 - 23 Apr 2006 VOL 144 ISS 17

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
**********************************************************
*                                                        *
*     CASREACT now has more than 10 million reactions    *
*                                                        *
**********************************************************
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 Apr 2006 (20060427/PD)
FILE LAST UPDATED: 27 Apr 2006 (20060427/ED)
HIGHEST GRANTED PATENT NUMBER: US7036150
HIGHEST APPLICATION PUBLICATION NUMBER: US2006090232
CA INDEXING IS CURRENT THROUGH 27 Apr 2006 (20060427/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 Apr 2006 (20060427/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

FILE MEDLINE
FILE LAST UPDATED: 26 APR 2006 (20060426/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 26 April 2006 (20060426/ED)

FILE EMBASE
FILE COVERS 1974 TO 27 Apr 2006 (20060427/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE JAPIO
FILE LAST UPDATED: 3 APR 2006 <20060403/UP>
FILE COVERS APRIL 1973 TO DECEMBER 22, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE. USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION ABOUT THE IPC REFORM <<<

FILE JICST-EPLUS
FILE COVERS 1985 TO 24 APR 2006 (20060424/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

Inventor Search

=> d ibib abs ind l16 1-3

L16 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:874984 HCAPLUS
DOCUMENT NUMBER: 139:333143
TITLE: Dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for the treatment of neuropsychiatric disorders secondary to organic impairments
INVENTOR(S): Mueller, Peter Sterling
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. 6,323,242.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207943	A1	20031106	US 2001-836156	20010417
US 6323242	B1	20011127	US 1998-204124	19981202
US 2002137798	A1	20020926	US 2002-92144	20020306
US 6696495	B2	20040224		
CA 2444269	AA	20021024	CA 2002-2444269	20020417
WO 2002083115	A1	20021024	WO 2002-US12011	20020417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1404308	A1	20040407	EP 2002-728788	20020417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527532	T2	20040909	JP 2002-580919	20020417
US 2004157934	A1	20040812	US 2003-750118	20031231
PRIORITY APPLN. INFO.:			US 1998-204124	A2 19981202
			US 2001-836156	A2 20010417
			US 2002-92144	A 20020306
			WO 2002-US12011	W 20020417

AB A method for treatment of neuropsychiatric symptoms or disorders emanating from primary brain or systemic impairments includes administration of an ED of a dopamine-, serotonin-, or norepinephrine-reuptake inhibitor to a human in need of such treatment. The preferred reuptake inhibitor is sibutramine.

IC ICM A61K031-135
INCL 514659000
CC 1-11 (Pharmacology)
ST dopamine reuptake inhibitor neuropsychiatric disorder org impairment; serotonin reuptake inhibitor neuropsychiatric disorder org impairment; norepinephrine reuptake inhibitor neuropsychiatric disorder org impairment; sibutramine neuropsychiatric disorder org impairment
IT Disease, animal
(Gulf war syndrome; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)

IT Buildings
(air pollution, Sick building syndrome; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Chromosome
(brain disorders of chromosomal disease; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Endocrine system, disease
(brain disorders of; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Pain
(complex regional pain syndrome; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Brain, disease
(cyst; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Metabolism, animal
(disorder, brain disorders of; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT 5-HT reuptake inhibitors
Analgesics
Brain, disease
Brain, neoplasm
Cognition enhancers
Cognitive disorders
Epilepsy
Human
Mental and behavioral disorders
Nervous system, disease
Nervous system agents
(dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Opioids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(endorphin-opioid pathol.; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Disease, animal
(genetic, brain disorders of; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Disease, animal
(reflex sympathetic dystrophy syndrome; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Eye, disease
Inflammation
(retinitis pigmentosa; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Indoor air pollution
(sick building syndrome; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Speech disorders

(stammering; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT Infection
(viral; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT 106650-56-0, Sibutramine 106650-56-0D, Sibutramine, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)
IT 60118-07-2, Endorphin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(endorphin-opioid pathol.; dopamine-, serotonin-, and norepinephrine-reuptake inhibitors for treatment of neuropsychiatric disorders secondary to organic impairments)

L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:736902 HCAPLUS
DOCUMENT NUMBER: 137:226639
TITLE: Treatment of disorders secondary to organic impairments with sibutramine
INVENTOR(S): Mueller, Peter Sterling
PATENT ASSIGNEE(S): Snowden Pharmaveuticals, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 836,156.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137798	A1	20020926	US 2002-92144	20020306
US 6696495	B2	20040224		
US 6323242	B1	20011127	US 1998-204124	19981202
US 2003207943	A1	20031106	US 2001-836156	20010417
CA 2444269	AA	20021024	CA 2002-2444269	20020417
WO 2002083115	A1	20021024	WO 2002-US12011	20020417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1404308	A1	20040407	EP 2002-728788	20020417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527532	T2	20040909	JP 2002-580919	20020417

US 2004157934 A1 20040812 US 2003-750118 20031231
PRIORITY APPLN. INFO.: US 1998-204124 A2 19981202
US 2001-836156 A2 20010417
US 2002-92144 A 20020306
WO 2002-US12011 W 20020417

AB A method for treatment of neuropsychiatric symptoms or disorders emanating from primary brain or systemic impairments includes administration of an ED of a dopamine, serotonin, and norepinephrine reuptake inhibitor to a human in need of such treatment. The preferred reuptake inhibitor is sibutramine.

IC ICM A61K031-137
INCL 514650000
CC 1-11 (Pharmacology)
ST head trauma neuropsychiatric symptom treatment sibutramine
IT Movement disorders
(cerebral palsy; treatment of disorders secondary to organic impairments with sibutramine)
IT Drug delivery systems
(controlled-release; treatment of disorders secondary to organic impairments with sibutramine)
IT Mental and behavioral disorders
(dementia, non-Alzheimer's dementia; treatment of disorders secondary to organic impairments with sibutramine)
IT Brain
(limbic system, neurogenesis; treatment of disorders secondary to organic impairments with sibutramine)
IT Mental and behavioral disorders
(psychosis; treatment of disorders secondary to organic impairments with sibutramine)
IT Muscle, disease
Nervous system, disease
(spasticity; treatment of disorders secondary to organic impairments with sibutramine)
IT Head and Neck, disease
(trauma; treatment of disorders secondary to organic impairments with sibutramine)
IT Alzheimer's disease
Anti-Alzheimer's agents
Human
Neurogenesis
(treatment of disorders secondary to organic impairments with sibutramine)
IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine
51-61-6, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitor; treatment of disorders secondary to organic impairments with sibutramine)
IT 106650-56-0, Sibutramine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of disorders secondary to organic impairments with sibutramine)

L16 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:383908 HCAPLUS
DOCUMENT NUMBER: 133:820
TITLE: Treatment of disorders secondary to organic impairments using a dopamine, serotonin, or norepinephrine reuptake inhibitor
INVENTOR(S): Mueller, Peter Sterling

PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032178	A2	20000608	WO 1999-US28362	19991201
WO 2000032178	A3	20001005		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6323242	B1	20011127	US 1998-204124	19981202
CA 2353133	AA	20000608	CA 1999-2353133	19991201
EP 1135115	A2	20010926	EP 1999-960633	19991201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003504303	T2	20030204	JP 2000-584874	19991201
AU 764049	B2	20030807	AU 2000-17488	19991201
PRIORITY APPLN. INFO.:			US 1998-204124 A	19981202
			WO 1999-US28362 W	19991201

AB A method for treatment of neuropsychiatric symptoms or disorders emanating from primary brain or systemic impairments includes administration of an ED of a dopamine, serotonin, or norepinephrine reuptake inhibitor to a human in need of such treatment. The preferred reuptake inhibitor is sibutramine.

IC ICM A61K031-00
CC 1-11 (Pharmacology)
ST neuropsychiatric symptom org disorder sibutramine; dopamine reuptake inhibitor neuropsychiatric symptom org disorder; serotonin reuptake inhibitor neuropsychiatric symptom org disorder; norepinephrine reuptake inhibitor neuropsychiatric symptom org disorder
IT Brain, disease
(Gilles de la Tourette syndrome; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Nervous system
(Huntington's chorea; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Mental disorder
(affective, including rage, violence, and intermittent explosive disorder and emotional problems; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Mental disorder
(attention deficit disorder; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Mental disorder
(attention deficit hyperactivity disorder; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)

IT Behavior
(automutilating; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Fatigue, biological
(chronic fatigue syndrome; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Brain
(cyst; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Endocrine system
(disease, brain disorder of; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Metabolism, animal
(disorder, brain disorder of; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Vision
(disorder, oscillopsia; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Behavior
Sexual behavior
Sleep
(disorder; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Analgesics
Antipsychotics
Biological transport
Brain, disease
Brain, neoplasm
Cognition enhancers
Fatigue, biological
Lupus erythematosus
Mental disorder
Nervous system agents
Psychotropics
(dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Opioids
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(endorphin-opioid pathol. and opiate addiction; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Muscle, disease
(fibromyalgia; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Brain
(frontal lobe, executive function; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Disease, animal
(genetic, brain disorder of chromosomal disease or; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Behavior
(motor, disorder, motor tics; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic

impairment)
IT Mental disorder
(obsession-compulsion; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Drug dependence
(opiate; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Mental disorder
(personality disorder, multiple personality disorder; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Mental disorder
(post-traumatic stress disorder; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Disease, animal
(primary organic impairment; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Mental disorder
(psychosis; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Epilepsy
(temporal lobe; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Infection
(viral; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT Behavior
(vocalization, vocal tics; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT 106650-56-0, Sibutramine 106650-56-0D, Sibutramine, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)
IT 60118-07-2, Endorphin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(endorphin-opioid pathol.; dopamine, serotonin, or norepinephrine reuptake inhibitor for treatment of disorder secondary to organic impairment)